Mcbi, Inc.

Kuraray Co., Ltd.

Canon Kabushiki Kaisha

Other

University of Tsukuba

Uchida, Kazuhiko

Hideaki Suzuki

Kohji Meno

Kazuhiko Uchida

Yusuke Ishida

Kozo Tamura

Kazushige Nishiyama

Takashi Ishi

Masahiro Kato

Go Tazaki

Yasushi Senda

Shimon Kanai

Toshiaki Hasegawa

Nobuhiro Oya

Yoshinori Nishimura

Hiroe Kumazawa

Hiroki Yamasaki

Yoshihiro Aoki

Hiroyuki Omichi

Meno Kohji

Takashi Ishii

Biomarkers for detecting cognitive dysfunction diseases and methods for detecting cognitive dysfunction diseases using the biomarkers are provided. A method for detecting cognitive dysfunction diseases comprising measuring one or more biomarkers for detecting cognitive dysfunction diseases selected from the following (a), (b), and (c) in a biological sample simultaneously or separately: (a) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of apolipoprotein A1 comprising the amino acid sequence represented by SEQ ID NO:1 or a partial peptide thereof; (b) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of transthyretin comprising the amino acid sequence represented by SEQ ID NO:2 or a partial peptide thereof; and (c) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of complement C3 comprising the amino acid sequence represented by SEQ ID NO:3 or a partial peptide thereof.

Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers

Methods are provided that detect cognitive impairment including mild cognitive impairment and Alzheimer disease by using a protein or its partial peptide that differs in presence or absence. Novel biomarkers are also provided for cognitive impairment and non-psychiatric disease, as well as methods for detecting cognitive impairment using such biomarkers. Specifically, a biomarker for diagnosis is provided that comprises a protein fragment or peptide of not less than 5 amino acid residues arising from at least one protein or peptide selected from the group of proteins consisting of an amino acid sequence expressed by SEQ ID NO: 1, 3, 6, 8, 10, 13, 15, 18, or 20 and selected from the group of partial peptide in these proteins consisting of an amino acid sequence expressed by SEQ ID NO: 2, 4, 5, 7, 9, 11, 12, 14, 16, 17, 19, or 21.

Biomarker for mental disorders including cognitive disorders, and method using said biomarker to detect mental disorders including cognitive disorders

This invention provides a method for detecting cognitive disfunction diseases including mild cognitive impairment and Alzheimer's disease using a protein and a peptide of the protein different in the presence level in subjects having a normal cognitive function and patients suffering from cognitive disfunction diseases and a biomarker for detecting cognitive disfunction diseases including mild cognitive impairment and Alzheimer's disease containing the protein and the peptide. This invention is a biomarker for diagnosing cognitive disfunction diseases containing a prothrombin precursor protein of SEQ ID NO: 1 or a peptide THRB containing the amino acid sequence represented by SEQ ID NO: 2 which is a peptide of the protein, a diagnosis method for cognitive disfunction diseases using the biomarker, an antigen peptide represented by SEQ ID NO: 3 for creating a THRB peptide specific antibody to be used in the diagnosis method, and a cognitive disfunction disease diagnosis kit containing the THRB peptide specific antibody.

Biomarker for cognitive dysfunction disease and method for detecting cognitive dysfunction disease using biomarker

The present invention relates to a modified hydrogenated product of a block copolymer having a polymer block (A) containing a structural unit derived from an aromatic vinyl compound, and a polymer block (B) containing a structural unit derived from a conjugated diene compound, a method of producing the modified hydrogenated product, and a resin composition containing the modified hydrogenated product. The modified hydrogenated product has one or more functional groups selected from an alkoxysilyl group, a carboxy group, an amino group, a hydroxy group, an epoxy group, and an acid anhydride-derived group, and satisfies the following conditions. Condition (1): after stay at 330&#xb0; C. for 30 min under nitrogen atmosphere, a weight change rate is &#x2212;5.5% or more. Condition (2): the peak top intensity of tan &#x3b4; measured in accordance with JIS K7244-10 (2005), under conditions including a strain amount of 0.1%, a frequency of 1 Hz, a measurement temperature of &#x2212;70 to 120&#xb0; C., and a temperature rise rate of 3&#xb0; C./min, is 1.0 or more.

Modified hydrogenated product, method for producing same, resin composition, and various uses thereof

The present invention aims to provide methods to detect cognitive impairment including mild cognitive impairment and Alzheimer disease by using a protein or its partial peptide that differs in presence or absence, or in quantity between non-cognitive impairment and patients with cognitive impairment and further aims to present biomarkers comprising said protein and said partial peptide to be used to detect cognitive impairment including Alzheimer disease or mild cognitive impairment. Specifically, a biomarker for diagnosis of psychiatry disease or cognitive impairment comprising protein fragment or peptide of not less than 5 amino acid residues arising from at least one protein or peptide selected from the group of proteins consisting of amino acid sequence expressed by SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25 and selected from the group of partial peptide in these proteins consisting of amino acid sequence expressed by SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 27. And further aims to provide diagnostic method using these biomarker.

Biomarkers for cognitive impairment and methods for detecting cognitive impairment using such biomarkers

A polyamide resin composition includes: 100 parts by mass of (A) a polyamide having a melting point of 280 to 330&#xb0; C.; 0.5 to 80 parts by mass of (B) aluminum diethylphosphinate; 0.2 to 2 parts by mass of (C) at least one phosphorous acid ester represented by formula (6) or (7); and (E) at least one reinforcing material. A mass ratio of the at least one phosphinic acid salt (B) to the at least one phosphorous acid ester (C) ((B)/(C)) is in a range of from 10 to 100. An average particle diameter of the phosphinic acid salt (B) is 0.1 to 100 &#x3bc;m. The polyamide resin composition does not comprise a metallic soap-based lubricant. 

Polyamide resin composition and molded article produced therefrom

The present invention aims to present methods to detect nonalcoholic fatty liver disease including nonalcoholic steatohepatitis by using a protein or its partial peptide that differs in presence or absence, or in quantity between healthy human subjects and patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis or between patients with fatty liver and nonalcoholic steatohepatitis and further aims to present biomarkers comprising said protein and said partial peptide to be used to detect nonalcoholic fatty liver disease including nonalcoholic steatohepatitis. Specifically, 35 kDa protein fragment consisting of amino acid sequence expressed by Sequence No. 2 and its partial peptide consisting of amino acid sequence expressed by Sequence No. 3 (including its glycated form) of inter-alpha-trypsin inhibitor heavy chain H4 precursor consisting of amino acid sequence expressed by Sequence No. 1 could be used as biomarkers to detect nonalcoholic fatty liver disease including nonalcoholic steatohepatitis.

Biomarkers for non-alcoholic fatty liver disease, and methods for detecting non-alcoholic fatty liver disease by using such biomarkers

The present invention provides a polyamide resin composition not only having an appropriate melt viscosity despite addition of a conductive filler thereto but also having excellent moldability, conductivity, low-temperature impact resistance, and fuel barrier properties. The present invention is a polyamide resin composition containing specific amounts of a polyamide, a modified resin, and a conductive filler. The polyamide contains: dicarboxylic acid units containing 50 mol % or more of terephthalic acid units and/or naphthalenedicarboxylic acid units; and diamine units containing 60 mol % or more of aliphatic diamine units having 4 to 18 carbon atoms, and has terminal amino groups in an amount of 5 to 60 &#x3bc;mol/g. The modified resin has been modified with an unsaturated compound having a carboxyl group and/or an acid anhydride group. In the polyamide resin composition, a difference between the number of moles (M) of the terminal amino groups of the polyamide and the number of moles (M) of the carboxyl groups and the acid anhydride groups of the modified resin in 1 g in total of the polyamide and the modified resin is &#x2212;5.0 &#x3bc;mol or more and less than 4.0 &#x3bc;mol, and the number of moles (M) is more than 4.0 &#x3bc;mol.

Resin composition and molded article containing the same

A multilayered tube for transporting fuel including an innermost layer (A), an outermost layer (B) and an intermediate layer (C), characterized by that: the innermost layer (A) and the outermost layer (B) include a resin composition including 40 mass % or more of semi-aromatic polyamide; a flexural modulus of a material constituting the intermediate layer (C) measured according to ISO 178 is 800 MPa or less; and it is used in an environment in which both the innermost layer (A) and the outermost layer (B) are contacted with biodiesel fuel. In addition, a fuel pump module including the multilayered tube for transporting fuel and a method for using them.

Multilayer tube for fuel transportation, fuel pump module provided with same, use of same, and use of fuel pump module

Biomarker for psychiatric diseases including cognitive impairment and methods for detecting psychiatric diseases including cognitive impairment using the biomarkers

An image forming apparatus includes: a developing unit for developing a latent image on an image bearing member by using a developer containing toner and a carrier; and a detecting unit for detecting a density of a detection reference toner image, wherein detection results obtained by the detecting unit are employed to control a toner replenishment operation for the developing unit, and wherein, when the detection results obtained by the detecting unit is equal to or smaller than a predetermined value, a residual toner amount determination mode is performed. The residual toner amount determination mode includes: a toner replenishment step of performing an operation for replenishing toner; a detecting step of performing the detecting unit to detect the density of the detection reference toner image; and a comparison step of comparing a first detection result obtained at the detection step with a second detection result obtained by the detecting unit before said toner replenishment step is performed the first time, and for which respective performance of the steps is enabled while an image forming operation is halted, and wherein, based on the results obtained at said comparison step, whether the residual toner amount determination mode should be continued is determined.

Image forming apparatus with a toner replenishment feature

This invention realizes and provides an image forming apparatus in which the presence or absence of a toner remaining in a toner storing portion is judged by a patch detecting method, characterized in that the wrong detection of the judgment of the presence or absence of the toner can be prevented and the lowering of image density can be suppressed. In an image forming apparatus having a first toner supply controller for controlling the driving time of a toner supplying portion on the basis of the video count number of the density signal of an image information signal, and a second toner supply controller for correcting the driving time of the toner supplying portion determined by the first toner controller, and designed such that the presence or absence of the toner remaining in the toner storing portion is judged on the basis of the density signal of a standard toner image, when the density signal of the standard toner image is equal to or less than a predetermined value, the driving time of the toner supplying portion additionally corrected per image by the second toner supply controller is made longer than when the density signal of the standard toner image is greater than the predetermined value.

Growing community of inventors

Tsukuba, Japan

Hideaki Suzuki